Download presentation
Presentation is loading. Please wait.
Published byFlorian Karsten Kramer Modified over 5 years ago
1
A randomized trial of antithrombin concentrate for treatment of heparin resistance
Mathew R Williams, MD, Alyssa B D’Ambra, BA, James R Beck, Talia B Spanier, MD, David L.S Morales, MD, David N Helman, MD, Mehmet C Oz, MD The Annals of Thoracic Surgery Volume 70, Issue 3, Pages (September 2000) DOI: /S (00)
2
Fig 1 Antithrombin (AT) activity at baseline, 30 minutes after commencing cardiopulmonary bypass (CPB), and at termination of CPB. Both groups had similarly deficient AT activity at baseline but there was a significant rise in activity in the AT concentrate group at the two later time points (p = and p = 0.009). (AT = antithrombin; CPB = cardiopulmonary bypass; ∗ denotes statistical significance.) The Annals of Thoracic Surgery , DOI: ( /S (00) )
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.